<qa>  What is the name of the PHASE I, MULTI-CENTER, OA PHASE I, MULTI-CENTER, OPEN LABEL, DRUG-DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF CERITINIB ON THE PHARMACOKINETICS OF WARFARIN AND MIDAZOLAM IN PATIENTS WITH ALK-POSITIVE ADVANCED TUMORS: 